Search results
Results from the WOW.Com Content Network
Supraventricular tachycardia (SVT) is an umbrella term for fast heart rhythms arising from the upper part of the heart. [2] This is in contrast to the other group of fast heart rhythms – ventricular tachycardia , which start within the lower chambers of the heart . [ 2 ]
Often sinus node dysfunction produces no symptoms, especially early in the disease course. Signs and symptoms usually appear in more advanced disease and more than 50% of patients will present with syncope or transient near-fainting spells as well as bradycardias that are accompanied by rapid heart rhythms, referred to as tachycardia-bradycardia syndrome [4] [5] Other presenting signs or ...
It can help to be aware of new treatment options—such as Ozempic and other GLP-1 drugs to reduce stroke risk in people with diabetes and a high risk of heart disease—and asking your doctor ...
An episode of supraventricular tachycardia due to AVNRT can be terminated by any action that transiently blocks the AV node. Some of those with AVNRT may be able to stop their attack by using physical manoeuvres that increase the activity of the vagus nerve on the heart, specifically on the atrioventricular node .
Heart disease, which includes heart attack and stroke, is the leading cause of death in the U.S., according to the Centers for Disease Control and Prevention (CDC).
Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a class of drugs that are used to suppress abnormally fast rhythms (tachycardias), such as atrial fibrillation, supraventricular tachycardia and ventricular tachycardia. Many attempts have been made to classify antiarrhythmic agents.
Future episodes can be prevented by catheter ablation. [3] About 2.3 per 1000 people have paroxysmal supraventricular tachycardia. [5] Problems typically begin in those 12 to 45 years old. [3] [5] Women are more often affected than men. [3] Outcomes are generally good in those who otherwise have a normal heart. [3]
Indications for Class Ia agents are supraventricular tachycardia, ventricular tachycardia, symptomatic ventricular premature beats, and prevention of ventricular fibrillation. Procainamide can be used to treat atrial fibrillation in the setting of Wolff–Parkinson–White syndrome , and to treat wide complex hemodynamically stable tachycardias .